Thorne HealthTech has received a CE mark certification for its at-home blood-sampling device, NanoDrop.

The clinical-grade device leverages the company’s new dual nano lancet technology to collect capillary whole-blood samples.

This technology is already incorporated into the company's OneDraw blood collection system.

The CE mark approval will now enable individuals to use the device for new testing applications at their homes.

Thorne HealthTech CEO Paul Jacobson said: “We consistently continue to find ways to improve the blood draw experience and with the dual nano lancet technology being a key part of the blood collection process, we look forward to making NanoDrop available across the European Union, which will allow more customers to experience and benefit from it.

“We believe this incremental news, combined with prior OneDraw clearance in Japan, puts Thorne one step closer to achieving broad application across end-markets around the globe.”

The company is focused on expanding its healthcare solution portfolio to offer painless blood collection options for at-home diagnostic testing and decentralised clinical trials.

Last month, Thorne announced the signing of a research and development partnership agreement with Arome Science to develop a new metabolomics test.

The companies agreed to work together to develop a commercial metabolomics wellness tes which will assist research studies by using the OneDraw device for at-home blood collection.

Thorne is claimed to be the only supplement manufacturer that works with Mayo Clinic on health and wellness research and content.